Introduction {#Sec1}
============

Cancer is one of the most serious medical problem and second leading cause of death in the world, characterized by a deregulation of the cell cycle which mainly results in a progressive loss of cellular differentiation and uncontrolled cellular growth. Hence there is a need to develop those agents whose chemical characteristics clearly differ from those existing agents and can overcome the problem of resistance. In present situation, the most engaged and demanding undertaking is the design, synthesis and development of new biologically active heterocycle compounds. Heterocyclic entities act as medications since they have precise synthetic reactivity and they give advantageous site to which bioactive substituents can be bind. Subsequently, there is need for the improvement of pharmacologically active heterocycles in synthetic and therapeutic science with certain focal points including its effortlessness of activity, greener methodology, simple workup strategy, selectivity, higher yields and high-particle monetary \[[@CR1], [@CR2]\].

In the medicinal field, the utility of heterocyclic entities has been raising each day because of structural similarities with biological molecules like nutrients, antibiotics. In spite of the fact that it including almost one-fourth of best hundred offering drugs yet because of issues like obstruction, poisonous quality, there is a requirement for minor change in existing drug molecules and to structure novel molecules which fuse benzimidazole as pharmacophore which are active against new targets \[[@CR3]\]. Substituted benzimidazole might be a vital pharmacophore in bioactive agent innovation. Recently, noticeably consideration has been given to the design and synthesis of substituted benzimidazoles. Current perceptions advocate that substituted benzimidazoles and heterocycles demonstrate interface with the biopolymers, have potential action with lower toxicities. The substituted benzimidazoles are helpful for the improvement of ongoing scaffolds of pharmaceutical or natural concern \[[@CR4]\].

Benzimidazole is also named as 3-azaindole, azindole, benziminazole, benzoglyoxaline, 3-benzodiazole, 1,3-diazaindene having melting point of 170--172 °C and occurs as white crystals \[[@CR5]\]. Benzimidazole is an important structural motif found in extensive number of natural and pharmacologically active molecules. Especially, the benzimidazoles might be considered as auxiliary isosters of nucleotides having attached heterocyclic cores in their structures, cooperate effortlessly with biopolymers and have potential action for chemotherapeutic applications \[[@CR6]\]. The benzimidazole moiety itself is an urgent pharmacophore in present day and has been used as privileged scaffolds to synthesize selective drugs of interest in numerous therapeutic areas including HIV-RT inhibitor \[[@CR7]\], anticancer \[[@CR8]\], antimicrobial \[[@CR9]\], antihistamine \[[@CR10]\], antihelmintic \[[@CR11]\], antioxidant \[[@CR12]\], antihypertensive \[[@CR13]\], antiviral \[[@CR14]\], anticoagulant \[[@CR15]\] and antiulcer activity \[[@CR16]\]. The marketed drugs having benzimidazole moiety (Fig. [1](#Fig1){ref-type="fig"}) i.e. (i) nocodazole, (ii) bendamustine, (iii) veliparib, (iv) glasdegib, (v) crenolanib, (vi) abemaciclib, (vii) liarozole, (viii) pracinostat. Malignancy is a gathering of various dangerous ailments described by uncontrolled development of cells, prompting attack of encompassing tissue and regularly spreading to different parts of the body \[[@CR17]\]. Development of resistance and toxicity to normal rapidly growing cells are the major limitations of existing anticancer drugs, also majority of the drugs in the market that are not specific \[[@CR8]\].Fig. 1Marketed drugs having benzimidazole moiety

Benzimidazole derivatives as antiproliferative agents {#Sec2}
-----------------------------------------------------

Abonia et al. synthesized new derivatives of 1,2,5-trisubstituted benzimidazole and screened for their antiproliferative activity against the 60 human cancer cell lines (leukemia, melanoma, lung, colon, brain, ovary, breast and kidney carcinoma etc.) using SRB protein assay to estimate cell growth. Among the synthesized compounds, compounds **1a** and **1b** (Fig. [2](#Fig2){ref-type="fig"}) displayed the utmost potency towards lung, melanoma and leukemia cancer cell lines (GI~50~ values 1.15--7.33 µM and 0.167--7.59 µM), respectively and LC~50~ values more than 100 µM \[[@CR6]\].Fig. 2Molecular structures of compounds (**1a**--**1b**, **2a**, **3a**, **4a**, **5a**, **6a**--**6b**, **7a, 8a**, **9a**, **10a**, **11a**--**11b**, **12a**--**12b**, **13a** and **14a**)

Azam et al. developed a new series of 2-substituted benzimidazoles and screened for its cytotoxicity against selected human tumor cell lines: leukemia (THP-1), MCF-7, PC-3 and adenocarcinomic alveolar basal epithelial cell line (A-549) by trypan blue exclusion method. Among the synthesized compound, **2a** exhibited promising activity against the tested cancer cell lines (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}) \[[@CR18]\].Table 1Percentage growth inhibition of compound **2a**CompoundConc. (µM)Cancer cell lines% Growth inhibitionMCF-7THP-1PC-3A-549**2a**1036394230509368607010096718189Adriamycin172------Paclitaxel1------65Mitomycin1----61--5-FU20--67---- Table 2Anticancer screening results of compound **2a**CompoundCancer cell lines (IC~50~ = µM)MCF-7THP-1PC-3A-549**2a**35 ± 248 ± 246 ± 143 ± 2

Coban et al. synthesized a new series of 1*H*-benzimidazole compounds and screened for its cytostatic studies using HeLa, MCF7 and A431 cancer cell lines by MTT assay. Compound **3a** exhibited the most profound cytotoxicity and comparable to standard drug (Table [3](#Tab3){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}) \[[@CR19]\].Table 3Anticancer screening results of compound **3a**CompoundCancer cell lines (IC~50~ = µM)A431HeLaMCF7**3a**6.166.046.94Doxorubicin0.190.160.31

Demirayak et al. reported a series of pyrazino\[1,2-*a*\]benzimidazole derivatives and evaluated for its in vitro anticancer activity against 60 human malignant cell lines: leukaemia (L), melanoma (M), NSCLC, CC, CNSC, OC, RC, PC and BC by SRB protein assay. Among the synthesized compounds, compound **4a** was found to be most active anticancer agent and comparable to standard drugs (Table [4](#Tab4){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}) \[[@CR20]\].Table 4Antiproliferative activity of compound **4a**CompoundCancer cell lines (Log GI~50~)LNSCLCCCCNSCMOCRCPCBCMG-MID**X**− 5.48− 5.17− 5.11− 5.12− 5.08− 5.18− 4.99− 4.49− 4.79− 5.09**Y**− 6.39− 6.20− 6.14− 6.18− 6.08− 6.45− 6.17− 6.41− 6.05− 6.20**4a**− 6.40− 4.40− 4.00− 4.92− 4.47− 4.00− 4.00− 4.00− 4.62− 4.63X: Melphalan; Y: *cis*-diaminedichloroplatinum

Dettmann et al. developed a new series of 2-phenyl-1-\[4-(2-piperidin-1-yl-ethoxy) benzyl\]-1*H*-benzimidazole derivatives and evaluated for its cytotoxicity against human MCF-7 and MDA-MB-231 breast cancer cell lines. Among the synthesized derivatives, compound **5a** displayed highest cytostatic effects (T/Ccorr ≈ 0%) and comparable to reference (T/Ccorr = 0--20%) effects at a concentration of 5 µM than the standard drug cisplatin (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR21]\].

Galal et al. synthesized a new class of benzimidazole-5-carboxylic acid derivatives and evaluated for its anticancer activity (growth inhibitory) against 21 human tumor cell lines (seven colon, eight lung and six gastric) by SRB assay. Compounds **6a** and **6b** showed 10 times superior inhibitory result than etoposide as reference (Table [5](#Tab5){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}) \[[@CR22]\].Table 5Anticancer activity (growth inhibitory) results of compounds (**6a** and **6b**)CompoundsGI~50~ (50% cell growth inhibition in µM)**6a**0.095**6b**0.091Etoposide1.3Doxorubicin0.065SN-380.066Cisplatin3.9

Gao et al. synthesized a novel series of benzimidazole acridine derivatives and evaluated for its in vitro cytotoxicity toward human erythroleukaemia K562 and malignant hepatoma HepG-2 cells by MTT assay. From this series, compound **7a** exhibited maximum cytotoxicity against both K562 (IC~50~ = 2.68 µM) and HepG-2 (IC~50~ = 8.11 µM) cells as compared to standard drugs colchicin (IC~50~ = 1.80 µM for HepG-2) and imatinib (IC~50~ = 0.47 µM for K562) (Table [6](#Tab6){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}) \[[@CR23]\].Table 6Anticancer activity results of compound **7a**CompoundCancer cell linesIC~50~ (µM)U2512.39**7a**A3753.20A1722.86Hela2.76CNE-22.62U118-MG1.98

Gellis et al. synthesized novel benzimidazole-4,7-dione molecules and evaluated for their cytotoxicity on colorectal, breast and lung cancer cell lines using MTT assay. Among the synthesized compounds, compound **8a** showed tremendous activity (IC~50~ ± 3 µM) and comparable to mitomycin C with IC~50~ ± 0.9 µM (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR24]\].

Gowda et al. reported a new series of benzimidazole-5-carboxylic acid derivatives and evaluated for its anticancer activity on K562 and CEM cancer cell using DMSO as vehicle control by the trypan blue and MTT assays. In this series, compound **9a** exhibited maximum apoptosis in leukemic cell accompanying an IC~50~ = 3 µM (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR25]\].

Guan et al. developed a new class of benzimidazole carbamates with indole moiety and accessed for its antiproliferative activity against three tumor cell lines (SGC-7901, A-549 and HT-1080) using MTT assay. In this series, compound **10a** displayed the highest antiproliferative activity towards selected cancer cell lines (Table [7](#Tab7){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}) \[[@CR26]\].Table 7Anticancer screening results of compound **10a**CompoundCancer cell lines (IC~50~ = µM)SGC-7901A-549HT-1080**10a**0.098 ± 0.0020.15 ± 0.050.13 ± 0.07Nocodazole0.080 ± 0.010.12 ± 0.030.14 ± 0.005

Hranjec et al. synthesized new benzimidazole substituted Schiff bases and evaluated for their in vitro antiproliferative activity toward human cancer cell lines i.e. HeLa (cervical carcinoma), SW620 (colorectal adenocarcinoma, metastatic), MiaPaCa-2 (pancreatic carcinoma), MCF-7 (breast epithelial adenocarcinoma, metastatic) and WI38 (normal diploid human fibroblasts) by MTT assay. From the synthesized compounds, compounds **11a** and **11b** displayed highest antiproliferative activity (Table [8](#Tab8){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}) \[[@CR27]\].Table 8Anticancer screening results of compounds (**11a** and **11b**)CompoundsCancer cell lines (IC~50~ = µM)HeLaMCF-7SW620MiaPaCa-2W138**11a**4.739.2349.1527.920.96**11b**3.2415.2752.0422.241.67

Hranjec et al. synthesized a new series of novel benzimidazole derivatives and evaluated for its antiproliferative activity on five different cancer cell lines: HeLa, pancreatic (MiaPaCa-2), colon (SW 620), MCF-7 and lung (H 460) cell lines by MTT assay. Among them, compounds **12a** and **12b** displayed the highest activity on tested cell lines and demonstrated an exceptional selectivity for HeLa cells (Table [9](#Tab9){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}) \[[@CR28]\].Table 9Anticancer activity results of compounds (**12a** and **12b**)CompoundsCancer cell lines (IC~50~ = µM)HeLaMiaPaCa-2SW 620MCF-7H 460**12a**0.8 ± 0.44 ± 230 ± 513 ± 326 ± 13**12b**0.7 ± 0.24 ± 225 ± 411 ± 122 ± 2Cisplatin3 ± 0.64 ± 34 ± 112 ± 60.3 ± 0.04Doxorubicin0.04 ± 0.0090.01 ± 0.010.02 ± 0.010.04 ± 0.01Not tested

Husain et al. synthesized a new class of benzimidazole having oxadiazole and triazolo-thiadiazoles moiety and evaluated for its in vitro anticancer potential at concentration (10 µM) against NCI 60 cell lines by five dose assay. Compound **13a** displayed considerable growth reticence with GI~50~ efficacy from 0.49 to 48.0 µM especially in lung carcinoma cell HOP-92 (GI~50~ 0.49, TGI 19.9, LC~50~ \> 100 and Log~10~GI~50~ − 6.30, Log~10~TGI − 4.70, Log~10~LC~50~ \> − 4.00) (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR29]\].

Husain et al. synthesized benzimidazole derivatives associated with triazolo-thiadiazole and triazolo-thiadiazine nucleus and screened for their in vitro anticancer potential at only concentration (10^−5^ M) toward NCI 60 cell lines by five dose assay. Among the synthesized compounds, compound **14a** (Fig. [2](#Fig2){ref-type="fig"}) exhibited excellent results against 60 cell panel (MG-MID − 6.07, − 5.51 and − 4.85 value of log~10~ GI~50~, log~10~ TGI and log~10~ LC~50~, respectively) \[[@CR30]\].

Kamal et al. synthesized novel terphenyl benzimidazole derivatives and screened for their antitumor potency in tumor cells i.e. oral, lung, ovarian, cervix, colon, breast and prostate cells by SRB method. Among the synthesized compounds, compounds **15a** and **15b** showed significant anticancer potency with GI~50~ values vary from \< 0.1 to 2.11 µM, whereas the positive control reference adriamycin demonstrated the GI~50~ value from 0.1 to 7.25 µM (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR31]\].Fig. 3Molecular structures of compounds (**15a**--**15b**, **16a**--**16b**, **17a**--**17b**, **18a**, **19a**, **20a**--**20c**, **21a**, **22a**--**22b** and **23a**)

Kamal et al. synthesized novel 2-aryl 1,2,4-oxadiazolo-benzimidazole compounds and evaluated for their in vitro anticancer screening against 60 tumor cell lines by SRB method. In this series, compounds **16a** and **16b** displayed significant cytoxicity against the majority of tumor cells with GI~50~ range from 0.79 to 28.2 µM (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR32]\].

Lukevics et al. developed novel trimethylsilylpropyl substituted benzimidazole derivatives and screened for their anticancer activity on mouse hepatoma (MG-22A), human fibrosarcoma (HT-1080), mouse melanoma (B16), mouse neuroblastoma (Neuro 2A) and normal mouse fibroblast cells by MTT assay. In this series, compounds, **17a** and **17b** showed significant activity in mouse melanoma (B16) having TD~50~ from 0.001 to 0.008 µg/mL. In vivo screening of compound **17a** showed high anticancer activity toward sarcoma S-180 by 62% (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR33]\].

El-Nassan, synthesized a new series of benzimidazole derivatives and demonstrated for its in vitro anticancer activity on MCF7 by SRB assay. Among the synthesized derivatives, compound **18a** (IC~50~ = 0.0390 µM) exhibited promising antitumor activity (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR34]\].

Paul et al. synthesized novel coumarin--benzimidazole conjugates and tested for their in vitro anticancer potency on 60 cancer cell lines by SRB assay. In this series, compound **19a** was found to be most active agent against leukemia, breast, colon, prostate (PC-3) and melanoma (LOX IMVI) cancer cell lines, respectively and comparable to the standard drug (5-FU) (Table [10](#Tab10){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}) \[[@CR35]\].Table 10Percentage growth inhibitory value of compound 19aCancer cell linesCompound 19a5-FluorouracilLeukemia HL-60 (TB)80.5147.9 CCRF-CEM72.5257.1 K-56257.3442.3 MOLT-438.0343.1 RPMI-822646.6541.4Breast tumor T-47D70.6856.7 MDA-MB231/ATCC58.9178.1 MDA-MB-46848.37Not tested BT-54933.1037.8Colon tumor HCT-11662.2517.8 HCT-1572.6726.5Melanoma cancer LOX IMVI54.2930.4Prostate cancer PC-356.6958.2

Paul et al. designed and synthesized novel quinazoline and benzimidazole conjugates and evaluated in vitro for their antitumor activity on 60 human tumor cell lines at a dose of 10 µM. From this series, compounds **20a**, **20b** and **20c** were found to be most active against selected cancer cell lines (Table [11](#Tab11){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}) \[[@CR36]\].Table 11Antitumor activity results of compounds (**20a**--**20c**)CompoundsActivity (µM)MG-MID**20a**GI~50~1.64TGI3.28LC~50~5.50**20b**GI~50~0.81TGI2.08LC~50~4.47**20c**GI~50~4.52TGI15.9LC~50~57.1Quinazoline analogueGI~50~16.9TGI40.5LC~50~\> 100Benzimidazole analogueGI~50~18.1TGI33.4LC~50~56.7

Ramla et al. synthesized a novel series of benzimidazole derivatives and evaluated for its inhibitory activity against Burkitt's lymphoma by Epstein--Barr virus activation test. In this series, compound **21a** exhibited 12.3% inhibitory activity (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR37]\].

Ranganatha et al. synthesized new benzophenone--benzimidazole derivatives and evaluated for their in vivo tumor inhibition against EAC cells via three independent assays (trypan blue dye exclusion, MTT and LDH release assay) using DMSO as a vehicle control. Compounds, **22a** and **22b** exhibited the highest cytotoxic effect (IC~50~ \~ 10 μM and \~ 16 μM) among the synthesized derivatives (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR38]\].

Rashid et al. synthesized benzimidazoles with oxadiazole nucleus and evaluated for their in vitro anticancer activity at a single dose (10 µM) in NCI 60 cell line panel using SRB assay. In this series, compound **23a** with GI~50~ values between 0.79 and 17.8 µM showed significant anticancer activity against tested cell lines (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR17]\].

Reddy et al. synthesized novel pyrazole containing benzimidazole conjugates and screened for their anticancer activity (growth inhibition) against lung-A549, MCF-7, HeLa and human keratinocyte cells-HaCaT using MTT assay. Among the synthesized derivatives, compounds **24a**, **24b** and **24c** exhibited effective anti-proliferative activity toward cancer tested cell lines (Table [12](#Tab12){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR39]\].Table 12Anticancer activity results of compounds (**24a**--**24c**)CompoundsCancer cell lines (IC~50~ µM)A549MCF-7HeLaHaCaT**24a**1.810.831.76\> 50**24b**1.130.951.57\> 50**24c**1.341.171.63\> 505-Fluorouracil2.132.364.615.26Nocodazole1.871.62.838.9 Fig. 4Molecular structures of compounds (**24a**--**24c**, **25a**--**25e**, **26a**, **27a**, **28a, 29a**, **30a** and **31a**--**31c**)

Refaat et al. synthesized a novel series of 2-substituted benzimidazole derivatives and evaluated in vitro for its anticancer potency against HEPG2, MCF7 and HCT116 cell lines by SRB assay using doxorubicin as reference. Among the synthesized compounds, compounds **25a** and **25b** showed the highest potency against HEPG2 while compounds, **25c**, **25d** and **25e** showed promising activity against MCF7. Compounds, **25d** and **25e** showed moderate activity against HCT116 (Table [13](#Tab13){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR40]\].Table 13Anticancer activity results (IC~50~ and IC~90~ µM) of compounds (**25a**--**25e**)CompoundsCancer cell linesIC~50~DoxorubicinIC~90~Doxorubicin**25a**HEPG20.55 ± 0.050.59 ± 0.037.53 ± 0.066.82 ± 0.06**25b**HEPG20.55 ± 0.030.59 ± 0.037.62 ± 0.096.82 ± 0.06**25c**MCF72.15 ± 0.040.72 ± 0.0811.70 ± 0.178.77 ± 0.06**25d**MCF72.83 ± 0.030.72 ± 0.0812.63 ± 0.098.77 ± 0.06HCT 1163.72 ± 0.030.65 ± 0.0912.02 ± 0.077.32 ± 0.09**25e**MCF72.85 ± 0.150.65 ± 0.0913.25 ± 0.138.77 ± 0.06HCT 1163.75 ± 0.160.72 ± 0.0812.05 ± 0.067.32 ± 0.09

Rewcastle et al. synthesized a series of benzimidazole analogs and evaluated for its enzyme activity against the p110α, β and δ isoforms of PI3K using a lipid kinase assay and also assessed for their antitumor activity against two human cancer cells lines, NZOV9 (Y1021C mutation of p110α enzyme) and NZB5 (wild-type p110α enzyme) using cell proliferation assay. From this series, compound **26a** exhibited best enzyme potency and also inhibiting tumor growth by 56.3 ± 2.6% (Table [14](#Tab14){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR41]\].Table 14Anticancer activity results (enzyme and cellular inhibition) of compound **26a**Compoundp110α\
IC~50~ (nm)p110β\
IC~50~ (nm)p110δ\
IC~50~ (nm)NZB5\
IC~50~ (µm)NZOV9\
IC~50~ (µm)**26a**117.34.50.170.04

Rodionov et al. synthesized novel ferrocenylalkyl 2-mercaptobenzimidazole derivatives and screened for their in vivo antitumor activity against the murine solid tumor, carcinoma 755 (Ca755), transplanted in mice. Among the synthesized compounds, compound **27a** showed 87% tumor growth inhibition on carcinoma 755 at the dose of 250.0 mg/kg day as compared to control cisplatin (Fig. [4](#Fig4){ref-type="fig"}) \[[@CR42]\].

Salahuddin et al. synthesized a novel series of benzimidazole molecules and screened for its in vitro anticancer activity on leukemia, melanoma, lung, colon, CNS, ovarian, renal, prostate and breast cancer cell lines. From this series, compound **28a** displayed promising activity against MDA-MB-468 (breast cancer) and SK-MEL-28 (melanoma) (GP = 36.23 and 47.56, respectively) (Fig. [4](#Fig4){ref-type="fig"}) \[[@CR43]\].

Sharma et al. synthesized new benzimidazole--quinazoline conjugates and monitor for their growth inhibitory activity on 60 tumor cell lines. Among them, compound **29a** exhibited superior activity on leukemia, colon and melanoma cancer cell lines as compared to standard 5-fluorouracil (Table [15](#Tab15){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR44]\].Table 15Percentage growth inhibitory results (GI %) of compound **29a**Cancer cell linesCompound 29a5-FluorouracilLeukemia K-56298.042.3 MOLT-450.043.1 RPMI-822645.041.4 SR94.224.8Colon HCC-299876.6Lethal HCC-11680.317.8 HT2994.327.1Melanoma LOX IMVI97.530.4

Sharma et al. synthesized novel purine-benzimidazole conjugates then screened for their anticancer activity against 60 human malignant cell lines by Aurora-A kinase assay. Among them, compound **30a** exhibited 1.25 fold more activity with GI~50~ value of 18.12 µM (MG-MID) than the reference 5-FU, GI~50~ = 22.60 µM (Fig. [4](#Fig4){ref-type="fig"}) \[[@CR45]\].

Yoon et al. synthesized a new class of benzimidazole derivatives and evaluated in vitro for its antiproliferative activity using human breast cancer MCF-7 and MDA-MB-468 cells by inner salt assay. From this series, compounds **31a**, **31b** and **31c** showed good antiproliferative activity against MCF-7 and MDA-MB-468 cells (Table [16](#Tab16){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR46]\].Table 16Anticancer activity (% cell inhibition) of compounds (**31a**--**31c**)CompoundsCancer cell linesMCF-7MDA-MB-468**31a**49.6346.33**31b**42.3745.51**31c**62.4342.30Cambinol38.2622.09

Yang et al. synthesized new symmetrical bis-benzimidazoles derivatives and evaluated in vitro for their cytotoxicity on HeLa, SKOV-3 and BGC-823 cell lines by MTT assay. In this series, compounds **32a**, **32b** and **32c** displayed significant activity against tested cancer cell lines (Table [17](#Tab17){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR47]\].Table 17Anticancer screening results of compound (**32a**--**32c**)CompoundsCancer cell lines (IC~50~ µM)SKOV-3HeLaBGC-823**32a**2.95\> 50\> 50**32b**38.607.116.4**32c**2.8132.411.0Cisplatin--1.61.3Taxol0.00134---- Fig. 5Molecular structures of compounds (**32a**--**32c**, **33a**, **34a**, **35a**, **36a, 37a**--**37b**, **38a**, **39a**--**39b** and **40a**)

Wang et al. synthesized new chain of benzene acyl-2-(1-methylindol-3-yl)-benzimidazole derivatives and screened for its tubulin polymerization inhibitory activity and cytotoxicity against anthropic A549, HepG2 and MCF-7 tumor cell lines by MTT assay. Among the synthesized derivatives, compound **33a** displayed excellent activity and comparable to colchicine and CA-4 as standards (Table [18](#Tab18){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR48]\].Table 18Cytotoxicity and tubulin polymerization inhibition of compound **33a**CompoundCancer cell lines\
(GI~50~ µM)Inhibition of tubulin polymerizationHepG2A549MCF-7(IC~50~ µM)**33a**3.82.45.11.5**CA-4**7.42.89.41.8Colchicine10.54.413.52.62

Wang et al. reported novel benzimidazole-2-urea derivatives and tested for their antiproliferative activity against a group of human tumor cells using MTT assay. In this series, compound **34a** exhibited the potent antiproliferative activity and compared to standard drugs (Table [19](#Tab19){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR49]\].Table 19Anticancer activity results (IC~50~ µM) of compound **34a**CompoundCancer cell linesNCI-H460Colo205K562A431HepG2HelaMDA-MB-435S**34a**0.0400.0500.0060.0261.7740.4520.052Colchicine0.0210.0030.0010.0081.7100.7040.007Taxol0.0100.0030.0040.0070.9900.4100.009

Madabhushi et al. synthesized some new benzimidazole functionalized chiral thioureas and screened for their cytotoxic activity against the human cancer cell lines (A549, MCF7, DU145 and HeLa) by MTT assay. From the synthesized compounds, compound **35a** found to display significant activity against A549, DU145 and HeLa cell lines (Table [20](#Tab20){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR50]\].Table 20Anticancer activity results IC~50~ (µM) of compound **35a**CompoundCancer cell linesA549MCF7DU145HeLa**35a**5.29.812.311.1Doxorubicin0.80.70.80.6

Yadav et al. designed and synthesized a series of new benzimidazole derivatives and accessed for its cytotoxic potential against MCF7 (human breast adenocarcinoma cancer) cell line by SRB technique and compared to 5-FU and carboplatin standard drugs. In this series, compound **36a** displayed the most potent anticancer activity (Table [21](#Tab21){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR51]\].Table 21Anticancer activity results of synthesized compound **36a**CompoundCancer cell line (IC~50~ = μM)MCF7**36a**0.0013**5-FU**0.0461Carboplatin0.2694

Yadav et al. synthesized some 2-(1-benzoyl-1*H*-benzo\[*d*\]imidazol-2-ylthio)-*N*-substituted acetamide derivatives and evaluated for their anticancer activity against MCF7 and HCT116 cancer cell lines by SRB assay using tamoxifen and 5-FU as references. Among the synthesized compounds, compounds **37a** and **37b** emerged out as excellent anticancer agents (Table [22](#Tab22){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR52]\].Table 22Anticancer screening results of compounds (**37a** and **37b**)CompoundsCancer cell lines (IC~50~ = μM/mL)MCF7HCT116**37a**0.00470.0839**37b**0.07860.0058Tamoxifen0.0043--5-FU--0.0125

Yadav et al. synthesized a class of novel benzimidazole derivatives and screened for its antitumor potency towards HCT116 cancer cell line by SRB method and comparable to standard drug 5-FU. Compound **38a** showed prominent antitumor activity (Table [23](#Tab23){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR53]\].Table 23Anticancer screening results of compound **38a**CompoundCancer cell line (IC~50~ = μM/mL)HCT116**38a**0.000055-FU0.00615

Tahlan et al. synthesized a series of new 2-mercaptobenzimidazole Schiff base derivatives and evaluated for its antitumor potency against HCT116 cancer cell line by SRB method using 5-FU as reference. In this series, compounds **39a** and **39b** showed significant antitumor activity towards tested cell line (Table [24](#Tab24){ref-type="table"} and Fig. [5](#Fig5){ref-type="fig"}) \[[@CR8]\].Table 24Anticancer activity results of synthesized compounds (**39a** and **39b**)CompoundsCancer cell line (IC~50~ = μg/mL)HCT116**39a**8**39b**75-FU2.63

Tahlan et al. reported a class of novel benzimidazole azomethine derivatives and screened for its anticancer potency against HCT116 cancer cell line by SRB method using 5-FU as standard. Among the synthesized compounds, compound **40a** was found to be most potent anticancer agent against selected cancer cell line (Table [25](#Tab25){ref-type="table"} and Fig. [5](#Fig5){ref-type="fig"}) \[[@CR9]\].Table 25Anticancer activity results of synthesized compound **40a**CompoundCancer cell line (IC~50~ = μg/mL)HCT116**40a**305-FU0.85

Mohammed et al. synthesized a class of new substituted benzimidazoles and screened for its anticancer activity against breast adenocarcinoma MCF-7, lung carcinoma A549 and epithelioid cervix carcinoma HeLa using SRB colorimetric assay. Among the synthesized compounds, compounds **41a** and **41b** were found to be most active anticancer agents and comparable to the cisplatin (reference drug) (Table [26](#Tab26){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR54]\].Table 26Percentage inhibition results of tested compounds (**41a** and **41b**)CompoundsCancer cell linesMCF-7HELAA549**41a**955477**41b**803572Cisplatin603560 Fig. 6Molecular structures of compounds (**41a**--**41b**, **42a**--**42c**, **43a**--**43b**, **44a**--**44b**, **45a**, **46a** and **47a**)

Aikman et al. developed some gold(III) pyridine-benzimidazole complexes and evaluated for their antitumor activity against human SKOV-3, A375, MCF-7 and A549 cancer cell lines by MTT assay using Auphen (stock solution 10 mM in DMSO) as reference. Compounds **42a**--**42c** showed promising anticancer activity, particularly in the melanoma A375 cancer cell line (Table [27](#Tab27){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR55]\].Table 27Anticancer activity results of synthesized compounds (**42a**--**42c**)CompoundsCancer cell lines (EC~50~ (µM))SKOV-3A375MCF-7A549**42a**17 ± 75 ± 212 ± 1\> 50**42b**33 ± 512 ± 229 ± 8\> 50**42c**41 ± 1313 ± 217 ± 345 ± 3Auphen7.00 ± 2.001.7 ± 0.33.00 ± 0.051.07 ± 0.09

Onnis et al. synthesized a series of novel benzimidazolehydrazones and evaluated for its anticancer activity against murine leukemia (L1210), T-lymphoblastic leukemia (CEM), cervix carcinoma (HeLa) and pancreas carcinoma (Mia Paca-2) cell lines. In this series, compounds **43a** and **43b** inhibited the growth of all tested cell lines (Table [28](#Tab28){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR56]\].Table 28Anticancer screening results of compounds (**43a** and **43b**)CompoundsCancer cell lines (IC~50~ = µM)L1210CEMHeLaMia Paca-2**43a**1.6 ± 0.90.98 ± 0.024.0 ± 0.46.3 ± 3.2**43b**2.9 ± 1.31.0 ± 0.012.5 ± 1.47.9 ± 0.3

Tahlan et al. designed and synthesized a series of substituted benzimidazole benzamide derivatives and screened for its anticancer potency against HCT116 cancer cell line by SRB method using 5-FU as standard. In this series, compound **44a** and **44b** were found to be most potent compounds against tested cell line (Table [29](#Tab29){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR57]\].Table 29Anticancer activity results of synthesized compounds (**44a** and **44b**)CompoundsCancer cell line (IC~50~ = μM)HCT116**44a**5.85**44b**4.535-FU9.99

Tahlan et al. designed and synthesized some novel benzimidazole derivatives and accessed for their antiproliferative potential towards HCT116 cancer cell line by SRB method. Among the synthesized derivatives, compound **45a** displayed the most potent anticancer activity (Table [30](#Tab30){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR58]\].Table 30Anticancer activity results of synthesized compound (**45a**)CompoundCancer cell line (IC~50~ = μM)HCT116**45a**4.125-FU7.69

Wang et al. developed a class of novel substituted benzimidazole derivatives and evaluated its antiproliferative activity against MGC-803, MCF-7, HepG2 and MFC cells by MTT colorimetric assay. In this class, compound **46a** showed remarkable anticancer activity as compared with standard drugs 5-FU and chrysin (Table [31](#Tab31){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR59]\].Table 31Anticancer activity results of synthesized compound (**46a**)CompoundCancer cell lines (IC~50~ = μM)MGC-803MCF-7HepG2MFC**46a**36.66 ± 4.7673.21 ± 2.4153.25 ± 3.2625.72 ± 3.955-FU74.39 ± 2.0357.09 ± 3.1763.37 ± 2.5278.52 ± 3.92Chrysin\> 100\> 10073.29 ± 3.8195.64 ± 5.04

El-Gohary et al. designed and synthesized a class of novel benzimidzole scaffolds and screened for its in vitro antiproliferative activity against three different cancer cell lines i.e. HepG2, HCT-116, MCF-7 and normal (W138) cell lines employing MTT assay. Among the synthesized compounds, compound **47a** displayed significant antitumor activity and comparable to standard 5-FU (Table [32](#Tab32){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR60]\].Table 32In vitro anticancer activity results of synthesized compound (**47a**)CompoundCancer cell lines (IC~50~ = mM)HepG2HCT-116MCF-7W138**47a**0.0220.0140.0150.2985-FU0.0610.0410.04150.051

Conclusion {#Sec3}
==========

Benzimidazole is a promising category of bioactive heterocyclic compound that exhibit wide variety of biological activities because of its structural similarity with the naturally occurring nucleotides and also a focusable moiety in discovery of novel drug design in medicinal field. The present review summarizes the chemistry of various substituted benzimidazole derivatives with their antiproliferative significance towards the various cancer cell lines such as HCT116, MCF7, HepG2, HeLa, A549 and A431. Benzimidazole has established huge alertness in current time and is extremely significant heterocyclic pharmacophore in recent drug innovation and medicinal chemistry.

SRB

:   sulforhodamide B

MTT

:   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide

EAC

:   Ehrlich Ascites Carcinoma

LDH

:   lactate dehydrogenase

5-FU

:   5-fluorouracil

µM

:   micro mole

NSCLC

:   non-small-cell lung carcinoma

CC

:   colon cancer

CNSC

:   central nervous system cancer

OC

:   ovarian cancer

PC

:   prostate cancer

BC

:   breast cancer

RC

:   renal cancer

MCF7

:   breast adenocarcinoma 7

HCT116

:   human colorectal carcinoma

DMSO

:   dimethyl sulfoxide
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